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ABSTRACT
Objective To identify a suitable dosing regimen of the
CD22-targeted monoclonal antibody epratuzumab in
adults with moderately to severely active systemic lupus
erythematosus (SLE).
Methods A phase IIb, multicentre, randomised
controlled study (NCT00624351) was conducted with
227 patients (37–39 per arm) receiving either: placebo,
epratuzumab 200 mg cumulative dose (cd) (100 mg
every other week (EOW)), 800 mg cd (400 mg EOW),
2400 mg cd (600 mg weekly), 2400 mg cd (1200 mg
EOW), or 3600 mg cd (1800 mg EOW). The primary
endpoint (not powered for signiﬁcance) was the week
12 responder rate measured using a novel composite
endpoint, the British Isles Lupus Assessment Group
(BILAG)-based Combined Lupus Assessment (BICLA).
Results Proportion of responders was higher in all
epratuzumab groups than with placebo (overall
treatment effect test p=0.148). Exploratory pairwise
analysis demonstrated clinical improvement in patients
receiving a cd of 2400 mg epratuzumab (OR for 600 mg
weekly vs placebo: 3.2 (95% CI 1.1 to 8.8), nominal
p=0.03; OR for 1200 mg EOW vs placebo: 2.6
(0.9 to 7.1), nominal p=0.07). Post-hoc comparison of
all 2400 mg cd patients versus placebo found an overall
treatment effect (OR=2.9 (1.2 to 7.1), nominal p=0.02).
Incidence of adverse events (AEs), serious AEs and
infusion reactions was similar between epratuzumab and
placebo groups, without decreases in immunoglobulin
levels and only partial reduction in B-cell levels.
Conclusions Treatment with epratuzumab 2400 mg cd
was well tolerated in patients with moderately to
severely active SLE, and associated with improvements in
disease activity. Phase III studies are ongoing.
INTRODUCTION
Systemic lupus erythematosus (SLE) is a multisystem
autoimmune disease with a wide range of clinical
manifestations.
12Disease activity and rate of pro-
gression of organ system damage varies widely
among patients with SLE.
3 Owing to this heterogen-
eity, accurate prognosis in individual patients is difﬁ-
cult, and development of new therapies has been
challenging.
4 However, understanding of the
underlying pathogenesis of SLE is increasing and a
number of promising therapeutic targets have been
identiﬁed,
5 including B-cell function and activity.
6 Of
previously tested B-cell-targeted treatments, primary
endpoints were not met in two phase III randomised
controlled trials (RCTs) of rituximab,
78whereas the
efﬁcacy of belimumab was demonstrated in two
phase III RCTs,
91 0with subsequent regulatory
approval in the USA and in the European Union.
11 12
Epratuzumab is the ﬁrst humanised monoclonal
antibody to target CD22, a transmembrane sialo-
glycoprotein expressed on mature B-cell lineages
that inﬂuences migration and activation.
13–15 The
mechanism of action of epratuzumab is not yet
fully deﬁned, but data indicate that it selectively
modiﬁes B-cell activation and function.
16–18
Epratuzumab was ﬁrst studied in patients with SLE
in a small open-label study
19 and in two subsequent
RCTs (ALLEVIATE-1 and -2) in which patients
received standard of care plus epratuzumab (360 or
720 mg/m
2) or placebo in 12-week cycles for up to
48 weeks.
20–22 The ALLEVIATE trials were discon-
tinued prematurely because of interruption of drug
supply. Despite low overall numbers of patients
treated, analyses of British Isles Lupus Assessment
Group (BILAG) disease activity scores and cortico-
steroid doses at week 12 provided initial conﬁrm-
ation of efﬁcacy at a dose of 360 mg/m
2.
20 22
Here we report the primary results of EMBLEM
(NCT00624351), a 12-week, multicentre, phase IIb
RCT that assessed the efﬁcacy and safety of epratu-
zumab in patients with moderate-to-severe SLE
disease activity using a novel composite primary
endpoint, the BILAG-based Combined Lupus
Assessment (BICLA).
23 EMBLEM was designed to
identify appropriate epratuzumab dosing regimens
for study in phase III RCTs.
PATIENTS AND METHODS
Patients
All patients provided written informed consent.
The trial recruited male or female patients aged
≥18 years with SLE diagnosis according to the
revised classiﬁcation criteria of the American
College of Rheumatology and moderate-to-severe
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24 25
level A disease activity in ≥1 organ/system except renal or
central nervous system; or (2) BILAG 2004 index level B disease
activity in ≥2 organs/systems if no level A disease activity was
present and (3) a Systemic Lupus Erythematosus Disease
Activity Index 2000 (SLEDAI-2K)
26 total score ≥6. Before ran-
domisation, BILAG data for individual subjects were reviewed
and graded by an independent adjudication committee to ensure
entry criteria were met. Other inclusion criteria included posi-
tive for antinuclear antibody at screening and receipt of corti-
costeroids (5–60 mg/day prednisone or equivalent) at a stable
dose for ≥5 days before the ﬁrst dose of study medication. If
steroids were initiated or increased for treatment of the current
disease ﬂare, this must not have occurred >14 days prior to the
ﬁrst dose of study medication. Patients receiving antimalarials
must have done so for ≥12 weeks. Doses of antimalarials and
immunosuppressives must have been stable for ≥28 days prior
to ﬁrst dose, and unchanged throughout the study.
Exclusion criteria included: active severe neuropsychiatric or
renal manifestations of SLE (except mononeuritis multiplex of
>4 weeks); pregnancy or lactation in females; active infection
(including HIV or human T-cell lymphotropic virus type 1) or
history of chronic infection; agammaglobulinemia; T-cell deﬁ-
ciencies; antiphospholipid antibody syndrome or use of oral
anticoagulants or antiplatelet agents; malignancy (except treated
non-melanoma skin cancers); signiﬁcant haematologic abnor-
malities not attributed to SLE; vaccination during the study
(except tetanus); and recent treatment with investigational
monoclonal antibodies. Use of cyclophosphamide, cyclosporine,
pimecrolimus, sirolimus or tacrolimus was prohibited.
Study design and treatment
The trial was conducted between January 2008 and August
2009 at 47 centres in Belgium, Brazil, Hong Kong, Hungary,
India, Lithuania, Poland, Spain, Ukraine, UK and USA in
accordance with International Conference on Harmonization
and US Food and Drug Administration (FDA) guidance on good
clinical practise. The study protocol and informed consent
forms were approved by each centre’s independent ethics com-
mittee or institutional review board.
After a 14-day screening, patients were randomly assigned to
one of six treatment groups: placebo or epratuzumab 200 mg
cumulative dose (cd) (100 mg every other week (EOW)),
800 mg cd (400 mg EOW), 2400 mg cd (600 mg weekly),
2400 mg cd (1200 mg EOW), or 3600 mg cd (1800 mg EOW).
These regimens were selected based on results of the prior
ALLEVIATE studies with the aim of identifying effective and
ineffective doses. Randomisation was via an interactive voice
response system and was stratiﬁed according to disease activity
(presence/absence of BILAG level A disease) and use of con-
comitant immunosuppressives (yes/no). All patients, investiga-
tors and study staff were blinded to treatment with the
exception of an independent data safety monitoring board.
Epratuzumab (10 mg/ml) was prepared in glass vials for slow
intravenous infusion with phosphate-buffered saline (PBS).
Placebo was 0.04 M PBS, and was provided in vials identical in
number and appearance to the epratuzumab vials. Patients were
premedicated with 25–50 mg diphenhydramine and 500–
1000 mg acetaminophen 30–60 min before each infusion.
Infusions occurred at weeks 0, 1, 2 and 3; those randomised to
epratuzumab EOWreceived placebo on weeks 1 and 3. The main
time-points for postbaseline efﬁcacy evaluations were weeks 4, 8
and 12. At study completion, patients were offered entry into a
long-term, open-label study, or had a safety visit 12 weeks later.
Study endpoints
The primary endpoint was the responder rate at week 12 according
to a composite endpoint, BICLA,
23 that includes
BILAG-2004,
24 25 27 SLEDAI-2K,
26 Physician Global Assessment
of disease activity (PGA) and no treatment failure. The
BILAG-2004 index was selected as the central score on the basis of
its comprehensiveness, ability to capture partial improvement, and
the clinical relevance of its scoring system. BILAG assessments were
performed by the investigators, and grades were determined by an
independent central reader group. Requirements for BICLA
response were: (1) BILAG-2004 improvement (all A scores at base-
line improved to B/C/D, and all B scores improved to C or D); (2)
no worsening in disease activity (no new BILAG-2004 A scores and
≤1 new B score); (3) no worsening of total SLEDAI-2K score from
baseline; (4) no signiﬁcant deterioration (<10% worsening) in
100 mm visual analogue PGA and (5) no treatment failure (deﬁned
as non-protocol treatment, ie, new or increased immunosuppres-
sives or antimalarials; or increased or parenteral corticosteroids; or
premature discontinuation from study treatment). Following week
4, corticosteroid doses could be tapered off at the investigator’sd i s -
cretion, based on disease activity. Once tapered, corticosteroid
doses could only be increased again to the dose preceding the last
taper step; any larger increase was deemed a treatment failure. In
addition, at no time was an increase of the corticosteroids dose
above the baseline value allowed without meeting the deﬁnition of
treatment failure.
Secondary efﬁcacy endpoints included BICLA response at week
8, BILAG improvement and enhanced BILAG improvement at
week 12, and changes in mean total SLEDAI-2K scores and cor-
ticosteroid doses at week 12 versus baseline. BILAG improvement
was deﬁned as for the primary endpoint. Enhanced BILAG
improvement, representative of quiescent disease, was deﬁned as all
BILAG A or B scores at study entry improved to C or D, with no
new BILAG A score and ≤1 new B score in other organ systems.
Adverse events (AEs) were coded according to Medical
Dictionary for Regulatory Activities (MedDRA), V .8.0.
Laboratory tests included haematology, serum chemistry and
urinalysis, as well as SLE-associated parameters (eg, complement
components 3 and 4 (C3 and C4) levels, human antihuman anti-
body (HAHA) levels, B-cell (CD20+) and T-cell (CD3+)
numbers, and IgG, IgM, IgA and total immunoglobulin levels).
B-cell surface levels of CD22 were assessed by ﬂow cytometry.
Statistical analyses
The trial was not powered to detect statistically signiﬁcant dif-
ferences between arms, but to detect clinical improvement and
support pharmacokinetic/pharmacodynamic analyses. To achieve
this, 30–35 patients per arm were required. The primary efﬁcacy
analysis comprised a logistic regression model of treatment
response status (yes/no), which controlled for baseline disease
activity (BILAG A presence/absence) and use of concomitant
immunosuppressive agents at baseline (yes/no), and allowed esti-
mation of the overall treatment effect of epratuzumab.
Exploratory pairwise comparisons between individual epratuzu-
mab dose arms and placebo were also deﬁned, including OR,
95% CI and p values. The intention-to-treat (ITT) analysis
included all randomised patients. The safety analysis included
all ITT patients who received ≥1 dose of study medication.
RESULTS
Patients
Overall, 227 patients were randomised and included in the ITT
efﬁcacy analyses (ﬁgure 1). Two patients in the epratuzumab
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medication and were excluded from safety analyses, although
not from efﬁcacy analyses. Patient characteristics, including
demographics, disease severity and medication use were similar
between treatment groups at baseline (table 1).
Efﬁcacy
At week 12, the responder rate in the placebo arm (21.1%) was
lower than in the epratuzumab arms (ﬁgure 2A). The overall test
of treatment effect was not statistically signiﬁcant (p=0.148).
However, exploratory pairwise analysis of responder rates
demonstrated clinical improvements in patients receiving a cd of
2400 mg epratuzumab (OR for 600 mg weekly vs placebo: 3.2
(95% CI 1.1 to 8.8), p=0.03; OR for 1200 mg EOW vs placebo:
2.6 (95% CI 0.9 to 7.1), p=0.07). No notable improvements in
response rates were observed with lower doses of epratuzumab
(<2400 mg cd) or the 3600 mg cd (1800 mg EOW) dose.
Further, the response rate in a post-hoc combined arm of all 74
patients who received epratuzumab 2400 mg cd (600 mg weekly
or 1200 mg EOW) was higher than for placebo (OR 2.9 (1.2 to
7.1); nominal p=0.02) (ﬁgure 2A). Differences in BICLA
response rates were seen as early as week 8 between patients
receiving 2400 mg cd epratuzumab (600 mg weekly or 1200 mg
EOW) and those in the placebo arm (ﬁgure 2B). No differences
between the other epratuzumab arms and placebo were noted at
week 8 (data not shown).
BILAG improvement at week 12 was greatest in the epratuzu-
mab 600 mg weekly and 1200 mg EOW arms, with 51.4% and
40.5% of patients, respectively, showing BILAG or enhanced
BILAG improvement, compared with 28.9% in the placebo arm
(ﬁgure 3; all p>0.05). In analyses of the six body systems for
which ﬁve or more patients per treatment arm had baseline
disease activity that allowed assessment of response, resolution
of BILAG system disease activity (BILAG A/B at baseline to
BILAG D at week 12) was more common among patients
treated with epratuzumab 600 mg weekly than among those
receiving placebo: musculoskeletal (28.6% (10/35) vs 19.4%
(6/31)); mucocutaneous (28.1% (9/32) vs 12.9% (4/31)); cardio-
respiratory (100% (7/7) vs 29.4% (5/17)); neuropsychiatric
(83.3% (5/6) vs 18.2% (2/11)), constitutional (100% (7/7) vs
77.8% (7/9)) and renal (33.3% (2/6) vs 0% (0/5)). Epratuzumab
1200 mg EOW was associated with greater BILAG system
improvements than placebo in musculoskeletal (32.4% (11/34)
vs 19.4% (6/31)), mucocutaneous (21.9% (7/32) vs 12.9% (4/
31)), and neuropsychiatric (62.5% (5/8) vs 18.2% (2/11))
systems. The incidence of individual BILAG items within each
body system was small and not evenly distributed between treat-
ment arms, so is not further analysed here.
Changes from baseline to week 12 in total SLEDAI-2K and
PGA scores were also greatest in the 600 mg weekly and
1200 mg EOW arms, but not statistically signiﬁcantly different
from placebo. SLEDAI-2K mean±SD change from baseline in
the placebo group was −5.6±6.2, compared with −3.2±5.0,
100 mg EOW; −3.6±5.5, 400 mg EOW; −6.3±5.7, 1200 mg
EOW; −5.7±6.7, 600 mg weekly; and −3.2±6.7, 1800 mg
EOW . PGA mean±SD change from baseline was −22.0±19.5 in
the placebo group, compared with −12.3±21.9, 100 mg EOW ,
−11.8±24.2, 400 mg EOW; −14.4±17.6, 1200 mg EOW;
−16.0±18.6, 600 mg weekly; and −13.2±19.3, 1800 mg EOW .
Mean±SD changes in corticosteroid use (mg) at week 12
versus baseline were minimal: −2.0±5.5 (placebo); −3.4±9.2
(100 mg EOW); −1.7±4.1(400 mg EOW); −1.6±6.9 (1200 mg
EOW);−0.3±4.0 (1800 mg EOW); and −0.9±7.4 (600 mg
weekly). The subsets of patients in each arm receiving high
doses (>30 mg/day) of corticosteroids showed the same distri-
bution of responses as the overall treatment arms.
Safety
The most common AEs across all arms were headache, nausea,
upper respiratory tract infection and dizziness (table 2).
Incidence rates of AEs, serious AEs (SAEs) and infusion reac-
tions were similar across all arms and unrelated to epratuzumab
dose. No effect of epratuzumab on standard laboratory para-
meters was observed. No deaths were reported.
At week 12, no placebo-treated patients and four epratuzumab-
treated patients met the criteria for a positive HAHA result (one
receiving 100 mg weekly; three receiving 400 mg EOW). There
was no discernible relationship between AEs and a positive
HAHA result. Median levels of immunoglobulins stayed within
normal levels, although mild/moderate increases in median IgA
Figure 1 Patient disposition (intention-to-treat population) through EMBLEM.
Wallace DJ, et al. Ann Rheum Dis 2014;73:183–190. doi:10.1136/annrheumdis-2012-202760 185
Clinical and epidemiological researchand IgG were observed over time with epratuzumab (see table in
online supplementary material). At week 12, moderate reduc-
tions in B-cell counts relative to baseline were observed across all
groups (ﬁgure 4A). Surface levels of CD22 on peripheral B cells
were reduced in epratuzumab arms but not in patients receiving
placebo (ﬁgure 4B). No consistent trends in T-cell counts were
observed over time. No relationships between either autoanti-
bodies or SLE-associated laboratory parameters (such as C3 and
C4 levels) and treatment response were consistently observed.
DISCUSSION
This placebo-controlled phase IIb trial aimed to identify an efﬁ-
cacious and well-tolerated dosing regimen for epratuzumab in
patients with moderately to severely active SLE. The test of
overall treatment effect was not signiﬁcant; however, the sample
size for this study was not chosen based on statistical powering
requirements. Exploratory pairwise analysis using the BICLA
endpoint found a higher proportion of responders in all arms
than with placebo (23.7–45.9%, vs 21.1% placebo), but most
notably there were clinical improvements in the 600 mg weekly
(OR 3.2 (95% CI 1.1 to 8.8), nominal p=0.03) and 1200 mg
EOWarms (OR 2.6 (95% CI 0.9 to 7.1), nominal p=0.07) and
in a combined analysis of the two 2400 mg cd arms vs placebo
(OR=2.9 (1.2 to 7.1), nominal p=0.02). The beneﬁcial effects
of 2400 mg cd epratuzumab could be observed as early as week
8. Epratuzumab was well tolerated, with similar incidences of
AEs, SAEs and infusion reactions as placebo and decreases in
immunoglobulin levels outside normal ranges or changes in
laboratory parameters.
These data build on the results of the ALLEVIATE trials,
which provided preliminary evidence of the efﬁcacy and safety
of epratuzumab in patients with SLE.
20–22 The BICLA compos-
ite endpoint used in EMBLEM was developed following an
expert panel review of disease activity indices (DAIs) commonly
used in SLE trials.
23 BICLA is a robust, sensitive, composite,
endpoint incorporating multiple DAIs, each of which empha-
sises different aspects of SLE activity. Composite endpoints have
greater power than individual tools to identify differences
between treatment groups, which is particularly useful in SLE,
where patient populations are heterogeneous and disease
Table 1 Patient characteristics at baseline (ITT analysis unless otherwise indicated)
Placebo
(n=38)
Epratuzumab
200 mg cd
(100 mg EOW)
(n=39)
800 mg cd
(400 mg EOW)
(n=38)
2400 mg cd
(600 mg weekly)
(n=37)
2400 mg cd
(1200 mg EOW)
(n=37)
3600 mg cd
(1800 mg EOW)
(n=38)
Age, mean (SD) 41.1 (11.3) 41.0 (9.8) 38.6 (10.4) 37.2 (11.4) 37.2 (10.7) 38.0 (12.2)
Female, n (%) 33 (86.8) 36 (92.3) 35 (92.1) 37 (100) 37 (100) 35 (92.1)
Ethnicity, n (%)
Hispanic or Latino 2 (5.3) 8 (20.5) 5 (13.2) 5 (13.5) 5 (13.5) 5 (13.2)
Race, n (%)
Caucasian 30 (78.9) 27 (69.2) 32 (84.2) 32 (86.6) 25 (67.6) 30 (78.0)
Black 2 (5.3) 8 (20.5) 3 (7.9) 3 (8.1) 4 (10.8) 3 (7.9)
Asian 5 (13.2) 4 (10.3) 2 (5.3) 2 (5.4) 6 (16.2) 4 (10.5)
American Indian/Alaskan Native 0 0 0 0 0 1 (2.6)
Mixed race 1 (2.6) 0 1 (2.6) 0 2 (5.4) 0
Severe (BILAG A) disease by organ/system, n (%)*
Mucocutaneous 16 (42.1) 14 (35.9) 12 (31.6) 12 (32.4) 9 (24.3) 11 (28.9)
Musculoskeletal 10 (26.3) 16 (41.0) 9 (23.7) 12 (32.4) 13 (35.1) 13 (31.6)
Cardiorespiratory 9 (23.7) 5 (12.8) 8 (21.1) 4 (10.8) 6 (16.2) 11 (28.9)
Neuropsychiatric 1 (2.6) 2 (5.1) 5 (13.2) 0 2 (5.4) 7 (18.4)
Constitutional 1 (2.6) 2 (5.1) 1 (2.6) 1 (2.7) 2 (5.4) 0
Renal 0 0 1 (2.6) 0 0 0
Ophthalmic 0 0 1 (2.6) 1 (2.7) 0 0
Gastrointestinal 1 (2.6) 0 0 1 (2.7) 0 1 (2.6)
Haematological 0 0 1 (2.6) 0 0 0
At least one BILAG A 29 (76.3) 29 (74.4) 29 (78.4) 25 (67.6) 27 (69.2) 22 (62.9)
Total BILAG-2004 index score, median
(range)*†
15.0 (6, 28) 13.0 (6, 28) 13.0 (6, 33) 12.0 (6, 33) 14.0 (6, 37) 15.5 (6, 34)
Total SLEDAI-2K score, median (range)* 14.0 (6, 34) 12.0 (8, 24) 13.0 (8, 30) 10.0 (6, 41) 12.0 (6, 38) 13.0 (6, 28)
Total SLICC ACR score, median (range)* 1.0 (0, 5) 1.0 (0, 5) 1.0 (0, 5) 1.0 (0, 8) 0.0 (0, 7) 1.0 (0, 9)
Immunosuppressives, n (%)* 18 (47.4) 16 (41.0) 16 (43.2) 13 (37.1) 18 (48.6) 18 (46.2)
Antimalarials, n (%)* 18 (47.4) 16 (41.0) 16 (43.2) 16 (45.7) 18 (48.6) 17 (43.6)
Corticosteroid use, mg/day prednisone equivalent
Mean (SD)* 13.4 (10.6) 14.6 (12.8) 14.4 (10.5) 13.2 (10.6) 16.1 (9.9) 11.3 (8.1)
No baseline dose (%) 0 1 (2.6) 1 (2.6) 3 (8.1) 0 1 (2.6)
Dosage >30 mg/day, n (%)* 3 (7.9) 5 (12.8) 2 (5.4) 3 (8.6) 1 (2.7) 1 (2.6)
*Safety analysis.
†The total BILAG-2004 index score was based on the original convention of A=9; B=3; C=1; D=0; E=0;
28 updated numerical scoring was proposed for the BILAG-2004 index after this
study was initiated.
29
BILAG, British Isles Lupus Assessment Group; cd, cumulative dose; EOW, every other week; ITT, intention-to-treat; PGA, Physician’s Global Assessment; SLEDAI-2K, Systemic Lupus
Erythematosus Disease Activity Index 2000; SLICC ACR, Systemic Lupus International Collaborating Clinics American College of Rheumatology.
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33 0The BILAG-2004 index, used
as the key component of BICLA in EMBLEM, is a comprehen-
sive validated tool for assessing disease activity in all organ
systems, and is capable of measuring incremental improve-
ment.
27 For a patient to be classiﬁed as a BICLA responder,
improvements were required in all BILAG 2004 index organ
systems affected by the disease at baseline, a relatively stringent
response criterion. Notably, a low number of responders was
observed in the placebo arm using the BICLA endpoint.
Rules on background medication use were stringent, with any
increase from baseline dose of immunosuppressives, corticoster-
oids or antimalarial medication at any time during the study
classiﬁed as a treatment failure. Following week 4, corticosteroid
doses could be tapered off gradually according to the investiga-
tor’s assessment of disease activity. However, at week 12,
changes from baseline in corticosteroid use were minimal across
all arms, which may be because of the relatively low mean dose
at baseline (13.7 mg) and/or the short duration of the study.
Exploratory analyses showed that 600 mg weekly epratuzumab
was associated with greater resolution of disease activity in
BILAG 2004 systems than placebo in all six body systems that
could be evaluated, including the cardiorespiratory and neuro-
psychiatric systems. The study was not of sufﬁcient duration to
assess the effects of epratuzumab on SLE-associated damage.
Epratuzumab is one of a number of biological agents in devel-
opment for the treatment of SLE. Major targets of these agents
include B cells, Tcells and cytokines.
5 To date, however, success
has been limited by the challenges associated with measurement
of disease activity, the need for active background therapy in
clinical trials, and the importance of avoiding changes or
increases in background immunosuppressives and corticoster-
oids.
453 1Epratuzumab is the ﬁrst CD22-speciﬁc treatment to
be tested in clinical trials of SLE. In the EMBLEM trial, surface
levels of CD22 on peripheral B cells were reduced in patients
Figure 2 BILAG-based Combined Lupus Assessment response rate (A) at week 12 (intention-to-treat analysis) for all patient groups (B) over weeks
1–12 for the 2400 mg combined dose arms compared with the placebo group.
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In vitro studies have shown that epratuzumab induces CD22
phosphorylation and internalisation, which in turn leads to
modulation of B-cell activity.
15 Indeed, a decrease in the phos-
phorylation of Syk and phospholipase γ2a downstream
signalling events following activation of the B-cell receptor, as
well as inhibition of calcium ﬂux, have been observed following
epratuzumab treatment of B cells in vitro.
18 Unlike rituximab,
epratuzumab only partially reduces B-cell numbers and, there-
fore, it is possible to speculate that this agent may not be
Table 2 Adverse events (AEs) in the safety analysis
No. (%) patients
Placebo
(n=38)
Epratuzumab
200 mg cd (100 mg
EOW) (n=39)
800 mg cd (400 mg
EOW) (n=37)
2400 mg cd (600 mg
weekly) (n=35)
2400 mg cd (1200 mg
EOW) (n=37)
3600 mg cd (1800 mg
EOW) (n=39)
At least one AE 27 (71.7) 28 (71.8) 20 (54.1) 27 (77.1) 29 (78.4) 26 (66.7)
At least one
drug-related AE
8 (21.1) 12 (30.8) 10 (27.0) 13 (37.1) 16 (43.2) 12 (30.8)
AEs leading to
discontinuation
2 (5.3) 0 1 (2.7) 1 (2.9) 1 (2.7) 0
Serious AEs* 3 (7.9) 2 (5.1) 2 (5.4) 3 (8.6) 4 (10.8) 2 (5.1)
Infusion reactions 4 (10.5) 3 (7.7) 5 (13.5) 5 (14.3) 6 (16.2) 5 (12.8)
AEs possibly indicative
of infection
15 (39.5) 15 (38.5) 9 (24.3) 16 (45.7) 16 (43.2) 20 (51.3)
Most common AEs†
Headache 5 (13.2) 4 (10.3) 4 (10.8) 4 (11.4) 7 (18.9) 2 (5.1)
Nausea 2 (5.3) 3 (7.7) 2 (5.4) 3 (8.6) 3 (8.1) 5 (12.8)
Upper respiratory
Tract infection
2 (5.3) 2 (5.1) 0 1 (2.9) 3 (8.1) 6 (15.4)
Dizziness 0 1 (2.6) 2 (5.4) 1 (2.9) 3 (8.1) 3 (7.7)
Urinary tract infection 2 (5.3) 2 (5.1) 1 (2.7) 1 (2.9) 2 (5.4) 1 (2.6)
Pyrexia 2 (5.3) 2 (5.1) 1 (2.7) 0 1 (2.7) 1 (2.6)
Cough 3 (7.9) 0 0 1 (2.9) 0 1 (2.6)
Viral infection 2 (5.3) 0 0 1 (2.9) 1 (2.7) 0
Pneumonia 2 (5.3) 0 0 0 0 0
*Placebo: 1 case each of small intestinal obstruction, SLE and venous thrombosis; epratuzumab 100 mg EOW: 1 each of angina pectoris and rib fracture; epratuzumab 400 mg EOW: 1
each of haemorrhagic diarrhoea and anaphylactic reaction; epratuzumab 600 mg weekly: 1 each of non-cardiac chest pain, cholestasis and cervical carcinoma (diagnosed by biopsy
before screening: the patient discontinued the study); epratuzumab 1200 mg EOW: 1 each of abdominal pain, abdominal abscess, urinary tract infection, loss of consciousness and
lupus encephalitis; epratuzumab 1800 mg EOW: 1 each of headache and arterial thrombosis.
†Only AEs occurring in ≥5% of patients in the placebo or combined epratuzumab arms are shown. EOW, every other week; SLE, systemic lupus erythematosus.
Figure 3 Percentage of patients meeting criteria for BILAG improvement and enhanced BILAG improvement at week 12.
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increased risk of infection.
32 Indeed, no decreases in immuno-
globulin levels outside normal ranges were observed during
EMBLEM. Of note, some modulatory effects of epratuzumab
on B-cell activity are speciﬁc to SLE patients, such that the in
vitro proliferation of B cells is reduced by epratuzumab in SLE
patients but not in normal subjects.
16 Other studies have shown
that epratuzumab modulates expression of the adhesion mole-
cules CD62L, β7 and β1 integrin, and enhances the migration of
CD27-negative naive B cells towards the chemokine CXCL12.
17
Median B-cell counts decreased only moderately from baseline
in the active-treatment arms of EMBLEM. Additional work is
needed to fully deﬁne the mechanism of action of epratuzumab.
The mechanisms responsible for the low response rate seen with
the highest tested dose (3600 mg cd), although consistent with
the results of the earlier ALLEVIATE studies, also require
further investigation. High doses of epratuzumab may affect a
speciﬁc function of B cells, a particular subset of B cells, the
trafﬁcking of B cells into different anatomical compartments
and/or induce alternative signalling events not seen at lower
doses.
The results of the EMBLEM trial suggest that epratuzumab
can improve SLE disease activity, and support continued devel-
opment of this treatment. Phase III studies of epratuzumab have
been initiated (NCT01261793; NCT01262365). These placebo-
controlled studies will assess the efﬁcacy and safety of both
2400 mg cd regimens in patients with moderately to severely
active SLE over four 12-week treatment cycles. Such studies will
also provide insights into factors such as the sustainability of
treatment responses over time and the effects of epratuzumab
on steroid use and quality of life.
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